Retatrutide: Preclinical Research Overview
What is Retatrutide?
A peptide is a short chain of amino acids — the same building blocks that make up proteins. Retatrutide (also called LY3437943, made by Eli Lilly) is a lab-made peptide built to act on three different "receptors" at the same time. A receptor is like a lock on the surface of a cell, and a molecule that fits the lock and switches it on is called an agonist (think of it as a key that turns the lock on). Retatrutide acts on three of these locks: the GLP-1 receptor, the GIP receptor, and the glucagon receptor.
That is why it is called a triple agonist: it switches on (agonises) all three of these locks at once, not just one or two. Each of the three receptors helps control metabolism — the way the body handles energy, blood sugar (glucose), and fat. Because it hits all three at the same time, Retatrutide works in a more complicated way than older compounds that only act on one or two receptors.
The three receptor pathways Retatrutide acts on are:
- GLP-1 (Glucagon-Like Peptide-1) — a gut hormone receptor. In animal studies it is linked to releasing insulin (the hormone that lowers blood sugar), controlling appetite, and how fast the stomach empties
- GIP (Glucose-Dependent Insulinotropic Polypeptide) — a receptor found in fat tissue and in the insulin-making cells of the pancreas (beta cells). In animal studies it is looked at for its part in how the body handles fat and insulin
- Glucagon receptor — in lab research, linked to the liver releasing stored sugar and to how much energy the body burns
Retatrutide has been studied more than most research peptides like it. It has been through Phase 1 and Phase 2 clinical trials (early human studies done in steps to check safety and effects), and the results were published in well-known journals: the New England Journal of Medicine, The Lancet, and Cell Metabolism. All this published data makes it one of the most studied peptides you can find for incretin & receptor research.
Velox Peptides supplies Retatrutide as a lyophilised powder (freeze-dried into a dry powder) for in vitro research use only (test-tube and lab work only). It is HPLC-verified at ≥99% purity, checked by an outside lab (HPLC is a lab test that checks how pure something is). The batch report is available on request. View the Retatrutide product page →
Receptor Mechanisms in Preclinical Research
To understand how Retatrutide works, it helps to look at each of its three receptor "locks" on its own first, then see how they work together. The summaries below come from published research studies.
GLP-1 Receptor Pathway
GLP-1 (Glucagon-Like Peptide-1) receptors are found all over the body — in the insulin-making cells of the pancreas (beta cells), the brain and nerves, the gut, and other tissues. In animal studies, switching on GLP-1 receptors is linked to releasing more insulin (the hormone that lowers blood sugar), but only when blood sugar is up (this is what "glucose-dependent" means). It is also linked to the stomach emptying more slowly and to appetite-lowering signals in a part of the brain called the hypothalamus.[4]
The GLP-1 receptor pathway has been studied a lot in rodents and in monkeys, and switching on the GLP-1 receptor is the main way that the most-researched metabolic peptides work. Retatrutide uses this as one of its three actions.
GIP Receptor Pathway
GIP (Glucose-Dependent Insulinotropic Polypeptide) receptors are found in the pancreas beta cells, in fat tissue, in bone, and in the brain. In lab studies, switching on the GIP receptor is linked to releasing more insulin and, importantly, to changes in how fat tissue works — including signals for storing fat and for breaking it down (lipolysis means breaking down fat) in mice.
Scientists got interested in switching on GIP and GLP-1 together because the two seem to help each other rather than just doing the same job twice. Finan et al. showed in mice, monkeys, and early human studies that a single molecule switching on both GIP and GLP-1 gave bigger results in studies than either one alone.[2] Retatrutide builds on this by adding the glucagon receptor as a third action.
Glucagon Receptor Pathway
Glucagon receptors sit mostly in the liver cells (hepatocytes), where they control how much stored sugar the liver releases into the blood. In animal studies, switching on the glucagon receptor also seems to change how much energy the body burns, with some data pointing to more heat being made (thermogenesis means making body heat).
On its own, switching on the glucagon receptor raises blood sugar — the opposite of what the GLP-1 receptor does. So why put it in a triple agonist? The idea researchers are testing is that, when it works together with the GLP-1 and GIP actions, the overall effect on energy-burning and fat in studies may be bigger than GLP-1/GIP alone, while the insulin released by the GLP-1 and GIP pathways helps keep blood sugar in check at the same time.[5] Testing this idea was a big reason Retatrutide was made and studied.
Key Study Findings
The summaries below come from published research studies. Everything here is just what each study observed — research observations only, not advice and not therapeutic effects. Retatrutide is not approved for human use and is supplied for in vitro research only (test-tube and lab work only).
This Phase 2 randomised controlled trial enrolled 338 participants across multiple dose cohorts over 48 weeks. The study investigated retatrutide at doses ranging from 1mg to 12mg weekly. Researchers observed substantial reductions in mean body weight across the higher-dose groups at both the 24-week and 48-week assessments, with the largest reductions in the 12mg cohort. The study reported a tolerability profile broadly consistent with other GLP-1 class compounds, with gastrointestinal adverse events (nausea, vomiting, diarrhoea) reported most frequently in the early dose-escalation period. The authors concluded that further Phase 3 investigation was warranted.
Important note: This is human clinical trial data, not preclinical animal study data. Results in human trials do not necessarily predict in vitro or animal model outcomes, and vice versa.
PMID: 37366315 — NEJM 2023;389(6):514–526
This study characterised LY3437943 in rodent models and non-human primates prior to human trials. Researchers reported receptor binding affinity data demonstrating activity at all three receptor targets (GIP, GLP-1, glucagon), with selective potency profiles at each. In diet-induced obese mouse models, the study observed significant reductions in body weight, improvements in glucose tolerance parameters, and changes in lipid profiles compared to vehicle controls. Non-human primate data demonstrated pharmacokinetic properties consistent with once-weekly dosing, with a half-life supporting weekly administration. The study described LY3437943 as the first characterised triple GIP/GLP-1/glucagon receptor agonist to advance toward clinical development.
PMID: 35108511 — Cell Metab. 2022;34(6):882–898.e6
This Phase 1b multicentre, double-blind, placebo-controlled study investigated LY3437943 in participants with type 2 diabetes to characterise safety, tolerability, and pharmacokinetics at escalating doses. Researchers observed a mean half-life of approximately 7 days, consistent with once-weekly dosing. Pharmacokinetic modelling confirmed dose-proportional exposure across the studied dose range. Receptor engagement was confirmed biochemically. The study reported an adverse event profile consistent with GLP-1 class compounds, with no serious unexpected safety signals at doses studied. The authors noted the pharmacokinetic profile supported advancement to Phase 2 investigation.
PMID: 36356631 — Lancet. 2022;400(10366):1869–1881
How Retatrutide Differs From Other Research Peptides
Retatrutide is a step on from earlier compounds that only act on one or two receptors. The table below shows which receptor "locks" each of the three most-studied compounds in this group switches on.
| Mechanism | Semaglutide | Tirzepatide | Retatrutide (LY3437943) |
|---|---|---|---|
| GLP-1 receptor agonism | ✓ | ✓ | ✓ |
| GIP receptor agonism | ✗ | ✓ | ✓ |
| Glucagon receptor agonism | ✗ | ✗ | ✓ |
| Receptor targets | 1 | 2 | 3 |
| Research generation | First generation | Second generation | Third generation (triple) |
Retatrutide is a newer kind of research compound than the ones that act on only one or two GLP-1-type receptors. Adding the glucagon receptor on top of the GLP-1 and GIP pair gives it a third way of working — changing how the liver handles sugar and how much energy the body burns — which older research peptides do not have. Because it switches on all three receptors, Retatrutide is of real interest in current incretin & receptor research, especially for scientists trying to work out how much each receptor pathway adds to the metabolic results seen in studies.
Velox Peptides Supply Information
Retatrutide is supplied as a research reagent only. It is not a medicine, and it has not been checked or approved by the MHRA or FDA. Not for human or veterinary use. See our Research Use Policy.
References
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity. N Engl J Med. 2023;389(6):514–526. PMID: 37366315
- Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple GIP, GLP-1 and glucagon receptor agonist for glycemic control and weight loss. Cell Metab. 2022;34(6):882–898.e6. PMID: 35108511
- Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a Phase 1b, multicentre, double-blind, placebo-controlled, randomised study. Lancet. 2022;400(10366):1869–1881. PMID: 36356631
- Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72–130. PMID: 30120083
- Day JW, Ottaway N, Patterson JT, et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol. 2009;5(10):749–757. PMID: 19597484
Frequently Asked Questions
What is Retatrutide?
Retatrutide (LY3437943) is a synthetic peptide that acts as a triple agonist at GLP-1, GIP and glucagon receptors simultaneously. It was developed by Eli Lilly and has been studied in Phase 1 and Phase 2 clinical trials, making it one of the most clinically investigated research peptides in the triple agonist class. It is supplied by Velox Peptides for in vitro research use only.
What does triple agonist mean?
A triple agonist activates three different receptor types at once. Retatrutide activates GLP-1 receptors, GIP receptors and glucagon receptors — each involved in different aspects of metabolic signalling in preclinical research models. This distinguishes it from semaglutide (single agonist) and tirzepatide (dual agonist) as a third-generation research compound in this class.
How does Retatrutide differ from semaglutide or tirzepatide?
Semaglutide targets one receptor (GLP-1). Tirzepatide targets two (GLP-1 and GIP). Retatrutide targets all three — GLP-1, GIP and glucagon — making it a newer generation triple agonist and of significant interest in current incretin & receptor research. The addition of glucagon receptor agonism introduces a third mechanism (hepatic glucose output and energy expenditure modulation) not present in dual-agonist compounds.
What purity is Velox Peptides Retatrutide?
Velox Peptides Retatrutide is HPLC-verified at ≥99% purity. Batch documentation is available on request. To request a copy prior to ordering, email veloxpeps@gmail.com.
Is Retatrutide legal to buy in the UK?
Yes. Retatrutide is legal to purchase in the UK for in vitro research purposes. It is not licensed as a medicine and is not approved for human use. Velox Peptides supplies Retatrutide strictly as a research reagent in accordance with our Research Use Policy — not for human or veterinary consumption.
What form does Velox Peptides Retatrutide come in?
Retatrutide is supplied as lyophilised (freeze-dried) powder in 10mg and 20mg vials. It requires reconstitution with bacteriostatic water before use in research applications. Our reconstitution calculator can assist with concentration calculations.
